 Max Wohlauer
Concepts (380)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vascular Surgical Procedures | 18 | 2024 | 294 | 3.930 |
Why?
| | Endovascular Procedures | 9 | 2024 | 301 | 1.860 |
Why?
| | Peripheral Arterial Disease | 5 | 2025 | 457 | 1.310 |
Why?
| | Surgeons | 7 | 2024 | 260 | 1.250 |
Why?
| | Blood Coagulation Disorders | 10 | 2016 | 167 | 1.220 |
Why?
| | Blood Vessel Prosthesis Implantation | 6 | 2022 | 197 | 1.100 |
Why?
| | Shock, Hemorrhagic | 10 | 2024 | 165 | 1.080 |
Why?
| | Thrombelastography | 13 | 2020 | 150 | 1.050 |
Why?
| | Acute Lung Injury | 8 | 2015 | 279 | 1.030 |
Why?
| | Vascular System Injuries | 3 | 2023 | 73 | 1.010 |
Why?
| | Elective Surgical Procedures | 3 | 2024 | 164 | 0.970 |
Why?
| | Aortic Aneurysm, Abdominal | 4 | 2022 | 132 | 0.940 |
Why?
| | Wounds and Injuries | 13 | 2016 | 710 | 0.920 |
Why?
| | Leg Injuries | 1 | 2023 | 28 | 0.820 |
Why?
| | Diabetic Foot | 1 | 2022 | 25 | 0.800 |
Why?
| | Intermittent Claudication | 2 | 2022 | 118 | 0.800 |
Why?
| | Burnout, Professional | 4 | 2021 | 404 | 0.800 |
Why?
| | Blood Transfusion | 8 | 2016 | 295 | 0.750 |
Why?
| | Pneumonia, Viral | 3 | 2020 | 339 | 0.720 |
Why?
| | Coronavirus Infections | 3 | 2020 | 333 | 0.720 |
Why?
| | Mental Health | 3 | 2022 | 685 | 0.700 |
Why?
| | Cultural Diversity | 1 | 2021 | 62 | 0.700 |
Why?
| | Sexism | 1 | 2021 | 55 | 0.700 |
Why?
| | Ergonomics | 1 | 2020 | 23 | 0.690 |
Why?
| | Musculoskeletal Pain | 1 | 2020 | 34 | 0.680 |
Why?
| | Internship and Residency | 4 | 2020 | 1047 | 0.670 |
Why?
| | Aortic Aneurysm, Thoracic | 3 | 2017 | 127 | 0.670 |
Why?
| | Multiple Organ Failure | 4 | 2013 | 122 | 0.650 |
Why?
| | Aggression | 1 | 2021 | 200 | 0.640 |
Why?
| | Muscle Fatigue | 1 | 2020 | 99 | 0.640 |
Why?
| | Pandemics | 8 | 2023 | 1482 | 0.630 |
Why?
| | Foot | 1 | 2020 | 93 | 0.630 |
Why?
| | Continuity of Patient Care | 2 | 2012 | 272 | 0.630 |
Why?
| | Racism | 1 | 2021 | 127 | 0.620 |
Why?
| | Tendons | 1 | 2020 | 106 | 0.620 |
Why?
| | Betacoronavirus | 3 | 2020 | 248 | 0.620 |
Why?
| | Occupational Diseases | 1 | 2020 | 138 | 0.610 |
Why?
| | Axillary Artery | 2 | 2015 | 12 | 0.600 |
Why?
| | Lymph | 3 | 2015 | 32 | 0.590 |
Why?
| | Running | 1 | 2020 | 223 | 0.560 |
Why?
| | Attitude of Health Personnel | 3 | 2024 | 1094 | 0.550 |
Why?
| | Serum Albumin, Human | 1 | 2017 | 6 | 0.550 |
Why?
| | Vascular Diseases | 1 | 2020 | 240 | 0.550 |
Why?
| | Hypoalbuminemia | 1 | 2017 | 30 | 0.550 |
Why?
| | Curriculum | 3 | 2019 | 910 | 0.520 |
Why?
| | Research Design | 1 | 2022 | 1043 | 0.520 |
Why?
| | Blood Platelet Disorders | 2 | 2013 | 10 | 0.500 |
Why?
| | Ischemia | 6 | 2025 | 406 | 0.490 |
Why?
| | Axilla | 1 | 2015 | 45 | 0.490 |
Why?
| | Aneurysm, False | 1 | 2015 | 47 | 0.470 |
Why?
| | Osteosarcoma | 1 | 2015 | 71 | 0.460 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 1000 | 0.450 |
Why?
| | Soft Tissue Neoplasms | 1 | 2015 | 111 | 0.440 |
Why?
| | Humans | 64 | 2025 | 129248 | 0.440 |
Why?
| | Bone Neoplasms | 1 | 2015 | 231 | 0.410 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2021 | 1276 | 0.400 |
Why?
| | Matrix Metalloproteinase 13 | 1 | 2012 | 23 | 0.400 |
Why?
| | Physicians | 1 | 2021 | 859 | 0.400 |
Why?
| | Neutrophils | 4 | 2015 | 1207 | 0.400 |
Why?
| | Patient Handoff | 1 | 2012 | 30 | 0.400 |
Why?
| | Saline Solution, Hypertonic | 1 | 2012 | 40 | 0.400 |
Why?
| | Duodenal Neoplasms | 1 | 2012 | 21 | 0.390 |
Why?
| | Common Bile Duct Neoplasms | 1 | 2012 | 27 | 0.390 |
Why?
| | Carcinoma, Papillary | 1 | 2013 | 77 | 0.390 |
Why?
| | Ampulla of Vater | 1 | 2012 | 38 | 0.390 |
Why?
| | Intestinal Volvulus | 1 | 2012 | 13 | 0.390 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2012 | 89 | 0.390 |
Why?
| | Colonic Diseases | 1 | 2012 | 32 | 0.390 |
Why?
| | Pancreatic Ducts | 1 | 2013 | 79 | 0.390 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2012 | 55 | 0.390 |
Why?
| | Blood Coagulation | 5 | 2021 | 238 | 0.380 |
Why?
| | Treatment Outcome | 18 | 2025 | 10199 | 0.380 |
Why?
| | Hemodilution | 1 | 2011 | 9 | 0.370 |
Why?
| | Multiple Trauma | 1 | 2012 | 101 | 0.370 |
Why?
| | Wounds, Penetrating | 1 | 2012 | 63 | 0.360 |
Why?
| | General Surgery | 1 | 2012 | 152 | 0.360 |
Why?
| | Male | 41 | 2025 | 63501 | 0.350 |
Why?
| | Patient Care Management | 1 | 2011 | 56 | 0.350 |
Why?
| | Time-to-Treatment | 2 | 2024 | 179 | 0.340 |
Why?
| | Rats, Sprague-Dawley | 9 | 2015 | 2396 | 0.340 |
Why?
| | Patient Transfer | 1 | 2012 | 148 | 0.340 |
Why?
| | Wounds, Nonpenetrating | 2 | 2015 | 271 | 0.330 |
Why?
| | Female | 38 | 2025 | 68543 | 0.330 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2013 | 270 | 0.330 |
Why?
| | Mesentery | 4 | 2015 | 47 | 0.320 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2024 | 248 | 0.320 |
Why?
| | Resuscitation | 3 | 2024 | 236 | 0.320 |
Why?
| | Risk Assessment | 9 | 2021 | 3233 | 0.300 |
Why?
| | Platelet Aggregation Inhibitors | 5 | 2022 | 442 | 0.290 |
Why?
| | Time Factors | 9 | 2025 | 6543 | 0.280 |
Why?
| | Thrombophilia | 2 | 2021 | 81 | 0.280 |
Why?
| | Risk Factors | 10 | 2025 | 9745 | 0.270 |
Why?
| | Computer Simulation | 1 | 2011 | 939 | 0.260 |
Why?
| | Anticoagulants | 4 | 2021 | 636 | 0.260 |
Why?
| | Aged | 12 | 2025 | 22032 | 0.260 |
Why?
| | Software | 1 | 2011 | 606 | 0.260 |
Why?
| | Rats | 8 | 2014 | 5482 | 0.260 |
Why?
| | Blood Platelets | 4 | 2014 | 380 | 0.250 |
Why?
| | Fibrinolysis | 3 | 2020 | 137 | 0.250 |
Why?
| | Education, Medical, Graduate | 2 | 2021 | 438 | 0.250 |
Why?
| | Adaptation, Psychological | 2 | 2021 | 614 | 0.250 |
Why?
| | Middle Aged | 22 | 2025 | 31087 | 0.250 |
Why?
| | Prospective Studies | 9 | 2022 | 7121 | 0.240 |
Why?
| | Adenocarcinoma | 1 | 2012 | 898 | 0.240 |
Why?
| | Balloon Occlusion | 2 | 2024 | 34 | 0.240 |
Why?
| | Retrospective Studies | 9 | 2025 | 14455 | 0.240 |
Why?
| | Diagnosis, Differential | 3 | 2015 | 1430 | 0.240 |
Why?
| | Pancreatic Neoplasms | 1 | 2013 | 881 | 0.240 |
Why?
| | Hospitals, Public | 1 | 2025 | 26 | 0.240 |
Why?
| | Adult | 25 | 2024 | 35495 | 0.230 |
Why?
| | Lower Extremity | 3 | 2023 | 404 | 0.230 |
Why?
| | Angiography | 2 | 2023 | 196 | 0.230 |
Why?
| | Health Surveys | 3 | 2021 | 493 | 0.220 |
Why?
| | Kidney | 1 | 2012 | 1385 | 0.220 |
Why?
| | Varicose Veins | 1 | 2024 | 17 | 0.220 |
Why?
| | Venous Thromboembolism | 2 | 2021 | 284 | 0.220 |
Why?
| | Patient Care Team | 2 | 2024 | 601 | 0.220 |
Why?
| | Brain Injuries | 3 | 2014 | 466 | 0.220 |
Why?
| | Injury Severity Score | 7 | 2016 | 509 | 0.220 |
Why?
| | Occupational Health | 3 | 2021 | 192 | 0.210 |
Why?
| | Heparin, Low-Molecular-Weight | 2 | 2014 | 29 | 0.210 |
Why?
| | Endarterectomy, Carotid | 1 | 2023 | 47 | 0.210 |
Why?
| | Hospital Mortality | 2 | 2021 | 846 | 0.200 |
Why?
| | Physician-Patient Relations | 2 | 2021 | 538 | 0.200 |
Why?
| | Arachidonic Acid | 2 | 2014 | 115 | 0.200 |
Why?
| | Ischemic Attack, Transient | 1 | 2023 | 60 | 0.200 |
Why?
| | Specialties, Surgical | 2 | 2020 | 73 | 0.200 |
Why?
| | Acute Disease | 5 | 2025 | 978 | 0.200 |
Why?
| | Carotid Stenosis | 1 | 2023 | 84 | 0.200 |
Why?
| | Prevalence | 3 | 2020 | 2554 | 0.200 |
Why?
| | United States | 10 | 2024 | 13828 | 0.190 |
Why?
| | Blood Coagulation Tests | 2 | 2020 | 60 | 0.190 |
Why?
| | Observational Studies as Topic | 1 | 2022 | 110 | 0.190 |
Why?
| | Pulmonary Embolism | 1 | 2024 | 211 | 0.190 |
Why?
| | Iliac Aneurysm | 1 | 2022 | 19 | 0.190 |
Why?
| | Arterial Occlusive Diseases | 1 | 2022 | 80 | 0.190 |
Why?
| | Point-of-Care Systems | 3 | 2012 | 147 | 0.190 |
Why?
| | Peripheral Vascular Diseases | 1 | 2022 | 101 | 0.190 |
Why?
| | Aorta | 1 | 2024 | 408 | 0.180 |
Why?
| | Arteriovenous Fistula | 1 | 2021 | 35 | 0.180 |
Why?
| | Aortic Rupture | 1 | 2021 | 25 | 0.180 |
Why?
| | Iliac Vein | 1 | 2021 | 11 | 0.180 |
Why?
| | Work Capacity Evaluation | 1 | 2020 | 11 | 0.180 |
Why?
| | Culturally Competent Care | 1 | 2021 | 57 | 0.170 |
Why?
| | Catheters | 1 | 2021 | 66 | 0.170 |
Why?
| | Vena Cava, Inferior | 1 | 2021 | 68 | 0.170 |
Why?
| | Physicians, Women | 1 | 2021 | 69 | 0.170 |
Why?
| | Tenotomy | 1 | 2020 | 13 | 0.170 |
Why?
| | Iatrogenic Disease | 1 | 2020 | 54 | 0.170 |
Why?
| | Tendon Transfer | 1 | 2020 | 24 | 0.170 |
Why?
| | Catheterization, Peripheral | 1 | 2021 | 104 | 0.160 |
Why?
| | Decompression, Surgical | 1 | 2020 | 95 | 0.160 |
Why?
| | International Cooperation | 1 | 2020 | 174 | 0.160 |
Why?
| | Societies, Medical | 2 | 2020 | 744 | 0.160 |
Why?
| | Workload | 3 | 2021 | 153 | 0.160 |
Why?
| | Posture | 1 | 2020 | 175 | 0.160 |
Why?
| | Thromboembolism | 1 | 2020 | 112 | 0.160 |
Why?
| | Infection Control | 1 | 2020 | 140 | 0.160 |
Why?
| | Partnership Practice | 1 | 2018 | 3 | 0.160 |
Why?
| | Mentors | 1 | 2021 | 178 | 0.160 |
Why?
| | Insurance Benefits | 1 | 2018 | 11 | 0.150 |
Why?
| | Venous Thrombosis | 1 | 2021 | 175 | 0.150 |
Why?
| | Catheterization, Central Venous | 1 | 2020 | 103 | 0.150 |
Why?
| | Physical Endurance | 1 | 2020 | 262 | 0.150 |
Why?
| | Health Services Needs and Demand | 1 | 2020 | 263 | 0.150 |
Why?
| | Surveys and Questionnaires | 7 | 2022 | 5382 | 0.150 |
Why?
| | Medically Uninsured | 1 | 2018 | 126 | 0.140 |
Why?
| | Pain Measurement | 1 | 2020 | 506 | 0.140 |
Why?
| | Triage | 1 | 2020 | 206 | 0.140 |
Why?
| | Walking | 1 | 2022 | 498 | 0.140 |
Why?
| | Registries | 2 | 2024 | 1895 | 0.140 |
Why?
| | Insurance Coverage | 1 | 2018 | 218 | 0.130 |
Why?
| | Statistics, Nonparametric | 3 | 2014 | 419 | 0.130 |
Why?
| | Biomechanical Phenomena | 1 | 2020 | 757 | 0.130 |
Why?
| | Nutrition Assessment | 1 | 2017 | 85 | 0.130 |
Why?
| | Purinergic P2Y Receptor Antagonists | 2 | 2014 | 66 | 0.130 |
Why?
| | Insurance, Health | 1 | 2018 | 265 | 0.130 |
Why?
| | Chronic Disease | 3 | 2024 | 1715 | 0.130 |
Why?
| | Aged, 80 and over | 5 | 2025 | 7055 | 0.130 |
Why?
| | Recovery of Function | 1 | 2020 | 641 | 0.130 |
Why?
| | Hemostatic Techniques | 1 | 2016 | 45 | 0.120 |
Why?
| | Practice Patterns, Physicians' | 2 | 2024 | 1267 | 0.120 |
Why?
| | Receptor, PAR-2 | 1 | 2015 | 6 | 0.120 |
Why?
| | Practice Guidelines as Topic | 2 | 2021 | 1497 | 0.120 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2015 | 26 | 0.120 |
Why?
| | Exsanguination | 2 | 2012 | 19 | 0.120 |
Why?
| | Motor Activity | 1 | 2020 | 675 | 0.120 |
Why?
| | Cohort Studies | 3 | 2022 | 5408 | 0.120 |
Why?
| | Sex Factors | 1 | 2021 | 1965 | 0.120 |
Why?
| | Plasminogen | 1 | 2015 | 31 | 0.120 |
Why?
| | Myocardial Infarction | 1 | 2022 | 1021 | 0.120 |
Why?
| | Geriatric Assessment | 1 | 2017 | 205 | 0.120 |
Why?
| | Biomedical Research | 1 | 2021 | 637 | 0.120 |
Why?
| | Microcirculation | 1 | 2015 | 145 | 0.120 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2015 | 85 | 0.120 |
Why?
| | Stroke | 1 | 2023 | 1070 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 1 | 2017 | 851 | 0.110 |
Why?
| | Down-Regulation | 1 | 2017 | 636 | 0.110 |
Why?
| | Medicaid | 1 | 2018 | 431 | 0.110 |
Why?
| | Animals | 10 | 2015 | 35307 | 0.110 |
Why?
| | Thrombin | 2 | 2015 | 145 | 0.110 |
Why?
| | Blood Vessel Prosthesis | 3 | 2022 | 123 | 0.110 |
Why?
| | Odds Ratio | 1 | 2017 | 1018 | 0.110 |
Why?
| | Frailty | 1 | 2017 | 153 | 0.110 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1197 | 0.110 |
Why?
| | Chi-Square Distribution | 2 | 2012 | 514 | 0.110 |
Why?
| | Limb Salvage | 2 | 2025 | 57 | 0.110 |
Why?
| | Medicare | 1 | 2018 | 706 | 0.110 |
Why?
| | Prosthesis Design | 3 | 2022 | 306 | 0.100 |
Why?
| | Subclavian Artery | 1 | 2013 | 27 | 0.100 |
Why?
| | Carotid Artery, Common | 1 | 2013 | 35 | 0.100 |
Why?
| | Fibrinogen | 1 | 2014 | 163 | 0.100 |
Why?
| | Postoperative Complications | 2 | 2021 | 2473 | 0.100 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2012 | 644 | 0.100 |
Why?
| | History, 17th Century | 1 | 2012 | 14 | 0.100 |
Why?
| | Comorbidity | 2 | 2021 | 1544 | 0.100 |
Why?
| | History, 18th Century | 1 | 2012 | 18 | 0.100 |
Why?
| | Brazil | 2 | 2025 | 154 | 0.100 |
Why?
| | History, 19th Century | 1 | 2012 | 57 | 0.100 |
Why?
| | Muscle, Skeletal | 1 | 2022 | 1613 | 0.100 |
Why?
| | Sigmoid Diseases | 1 | 2012 | 10 | 0.100 |
Why?
| | Colorado | 5 | 2016 | 4406 | 0.100 |
Why?
| | Social Responsibility | 1 | 2012 | 47 | 0.100 |
Why?
| | Anesthetics, Inhalation | 1 | 2012 | 27 | 0.100 |
Why?
| | Isoflurane | 1 | 2012 | 27 | 0.100 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 2012 | 42 | 0.100 |
Why?
| | Neutrophil Infiltration | 1 | 2012 | 105 | 0.100 |
Why?
| | Nebulizers and Vaporizers | 1 | 2012 | 83 | 0.100 |
Why?
| | Stress, Psychological | 1 | 2020 | 1065 | 0.100 |
Why?
| | Biopsy, Needle | 1 | 2012 | 189 | 0.100 |
Why?
| | 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 2011 | 6 | 0.100 |
Why?
| | Narration | 1 | 2012 | 57 | 0.100 |
Why?
| | Blood Transfusion, Autologous | 1 | 2011 | 16 | 0.100 |
Why?
| | Trauma Severity Indices | 1 | 2012 | 104 | 0.090 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2011 | 42 | 0.090 |
Why?
| | Efficiency, Organizational | 1 | 2012 | 133 | 0.090 |
Why?
| | Social Values | 1 | 2012 | 33 | 0.090 |
Why?
| | Depression | 1 | 2020 | 1306 | 0.090 |
Why?
| | Multivariate Analysis | 2 | 2013 | 1497 | 0.090 |
Why?
| | Proteomics | 3 | 2015 | 1054 | 0.090 |
Why?
| | Random Allocation | 1 | 2012 | 346 | 0.090 |
Why?
| | Colectomy | 1 | 2012 | 93 | 0.090 |
Why?
| | Renal Replacement Therapy | 1 | 2012 | 87 | 0.090 |
Why?
| | Survival Rate | 2 | 2016 | 1869 | 0.090 |
Why?
| | Kidney Function Tests | 1 | 2012 | 152 | 0.090 |
Why?
| | Extravascular Lung Water | 1 | 2011 | 7 | 0.090 |
Why?
| | History, 20th Century | 1 | 2012 | 291 | 0.090 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2011 | 33 | 0.090 |
Why?
| | Docosahexaenoic Acids | 1 | 2011 | 82 | 0.090 |
Why?
| | Hypothermia | 1 | 2011 | 34 | 0.090 |
Why?
| | Oxidative Stress | 3 | 2014 | 1265 | 0.090 |
Why?
| | Abdominal Pain | 1 | 2012 | 143 | 0.090 |
Why?
| | Abdominal Injuries | 1 | 2012 | 118 | 0.090 |
Why?
| | Administration, Inhalation | 1 | 2012 | 666 | 0.090 |
Why?
| | Efficiency | 1 | 2011 | 91 | 0.090 |
Why?
| | Aorta, Thoracic | 1 | 2013 | 262 | 0.090 |
Why?
| | Quality Assurance, Health Care | 1 | 2012 | 317 | 0.090 |
Why?
| | Health Care Surveys | 2 | 2024 | 557 | 0.090 |
Why?
| | Pancreatectomy | 1 | 2013 | 241 | 0.090 |
Why?
| | Superoxides | 1 | 2011 | 201 | 0.090 |
Why?
| | Proteome | 1 | 2014 | 438 | 0.080 |
Why?
| | Trauma Centers | 4 | 2016 | 402 | 0.080 |
Why?
| | Acidosis | 1 | 2011 | 89 | 0.080 |
Why?
| | Interprofessional Relations | 1 | 2012 | 275 | 0.080 |
Why?
| | Biomarkers | 3 | 2017 | 3966 | 0.080 |
Why?
| | Endothelial Cells | 1 | 2015 | 746 | 0.080 |
Why?
| | Logistic Models | 2 | 2012 | 1984 | 0.080 |
Why?
| | Cross-Sectional Studies | 4 | 2020 | 5045 | 0.080 |
Why?
| | Thrombosis | 1 | 2013 | 343 | 0.080 |
Why?
| | Quality Improvement | 2 | 2021 | 1095 | 0.080 |
Why?
| | Models, Animal | 1 | 2011 | 376 | 0.080 |
Why?
| | Safety | 1 | 2011 | 330 | 0.080 |
Why?
| | Recurrence | 1 | 2012 | 1005 | 0.080 |
Why?
| | Reperfusion Injury | 1 | 2011 | 272 | 0.070 |
Why?
| | Lymph Nodes | 1 | 2011 | 470 | 0.070 |
Why?
| | Disease Models, Animal | 3 | 2014 | 4057 | 0.070 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1691 | 0.070 |
Why?
| | Tissue and Organ Procurement | 1 | 2012 | 288 | 0.070 |
Why?
| | Adolescent | 5 | 2020 | 20303 | 0.070 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 1837 | 0.070 |
Why?
| | Lung | 3 | 2015 | 3926 | 0.070 |
Why?
| | Prognosis | 2 | 2013 | 3772 | 0.070 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 712 | 0.070 |
Why?
| | Chromatography, Liquid | 3 | 2014 | 424 | 0.060 |
Why?
| | Communication | 1 | 2012 | 836 | 0.060 |
Why?
| | Tandem Mass Spectrometry | 3 | 2014 | 523 | 0.060 |
Why?
| | Incidence | 1 | 2012 | 2636 | 0.060 |
Why?
| | Embolectomy | 1 | 2025 | 13 | 0.060 |
Why?
| | Clinical Competence | 1 | 2012 | 1016 | 0.060 |
Why?
| | Electronic Health Records | 1 | 2012 | 970 | 0.060 |
Why?
| | Databases, Factual | 2 | 2021 | 1266 | 0.060 |
Why?
| | Platelet Function Tests | 2 | 2014 | 25 | 0.050 |
Why?
| | Aortography | 2 | 2013 | 51 | 0.050 |
Why?
| | Reproducibility of Results | 1 | 2011 | 3079 | 0.050 |
Why?
| | Interdisciplinary Communication | 1 | 2024 | 184 | 0.050 |
Why?
| | Receptors, Purinergic P2 | 2 | 2013 | 23 | 0.050 |
Why?
| | Platelet Activation | 2 | 2014 | 91 | 0.050 |
Why?
| | Mesenteric Artery, Inferior | 1 | 2022 | 2 | 0.050 |
Why?
| | Off-Label Use | 1 | 2022 | 51 | 0.050 |
Why?
| | Carotid Arteries | 1 | 2023 | 196 | 0.050 |
Why?
| | Iliac Artery | 1 | 2022 | 55 | 0.050 |
Why?
| | Product Labeling | 1 | 2021 | 6 | 0.050 |
Why?
| | Cooperative Behavior | 1 | 2024 | 433 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 3 | 2018 | 2515 | 0.050 |
Why?
| | Blood Component Transfusion | 2 | 2012 | 82 | 0.050 |
Why?
| | Phlebography | 1 | 2021 | 37 | 0.040 |
Why?
| | Mitochondrial Proteins | 2 | 2015 | 248 | 0.040 |
Why?
| | Depersonalization | 1 | 2020 | 7 | 0.040 |
Why?
| | Protective Factors | 1 | 2021 | 91 | 0.040 |
Why?
| | Work-Life Balance | 1 | 2020 | 19 | 0.040 |
Why?
| | Fibrin Clot Lysis Time | 1 | 2020 | 9 | 0.040 |
Why?
| | Rivaroxaban | 1 | 2022 | 252 | 0.040 |
Why?
| | Personal Protective Equipment | 1 | 2020 | 49 | 0.040 |
Why?
| | Partial Thromboplastin Time | 1 | 2020 | 52 | 0.040 |
Why?
| | Heparin | 1 | 2021 | 253 | 0.040 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2020 | 82 | 0.040 |
Why?
| | Young Adult | 5 | 2014 | 12388 | 0.040 |
Why?
| | Aspirin | 1 | 2022 | 380 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2014 | 2008 | 0.040 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2020 | 528 | 0.040 |
Why?
| | Clinical Decision-Making | 1 | 2021 | 301 | 0.040 |
Why?
| | Popliteal Artery | 1 | 2018 | 58 | 0.040 |
Why?
| | Hemorrhage | 1 | 2022 | 678 | 0.040 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2018 | 98 | 0.040 |
Why?
| | Stents | 1 | 2022 | 502 | 0.040 |
Why?
| | Global Health | 1 | 2020 | 327 | 0.040 |
Why?
| | Military Personnel | 1 | 2024 | 515 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1584 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2020 | 351 | 0.030 |
Why?
| | Career Choice | 1 | 2019 | 206 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2021 | 526 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1004 | 0.030 |
Why?
| | Renal Dialysis | 1 | 2020 | 423 | 0.030 |
Why?
| | Alarmins | 1 | 2015 | 24 | 0.030 |
Why?
| | Emotions | 1 | 2020 | 538 | 0.030 |
Why?
| | Bacterial Translocation | 1 | 2015 | 40 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2014 | 3377 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2020 | 736 | 0.030 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2015 | 135 | 0.030 |
Why?
| | Tranexamic Acid | 1 | 2015 | 37 | 0.030 |
Why?
| | Pain | 1 | 2020 | 786 | 0.030 |
Why?
| | Inflammation | 2 | 2015 | 2737 | 0.030 |
Why?
| | Mesenteric Artery, Superior | 1 | 2013 | 15 | 0.030 |
Why?
| | Renal Artery | 1 | 2013 | 34 | 0.030 |
Why?
| | Extracellular Matrix Proteins | 1 | 2014 | 143 | 0.030 |
Why?
| | Glasgow Coma Scale | 1 | 2014 | 165 | 0.030 |
Why?
| | Age Factors | 1 | 2020 | 3140 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2014 | 479 | 0.030 |
Why?
| | Platelet Count | 1 | 2013 | 82 | 0.030 |
Why?
| | Blood Proteins | 1 | 2014 | 244 | 0.030 |
Why?
| | Receptors, Purinergic P2Y12 | 1 | 2012 | 6 | 0.030 |
Why?
| | Leukotriene C4 | 1 | 2012 | 11 | 0.020 |
Why?
| | Anastomosis, Surgical | 1 | 2013 | 149 | 0.020 |
Why?
| | Leukotriene B4 | 1 | 2012 | 42 | 0.020 |
Why?
| | Reference Values | 1 | 2014 | 793 | 0.020 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2012 | 38 | 0.020 |
Why?
| | Ticlopidine | 1 | 2012 | 54 | 0.020 |
Why?
| | Eicosanoids | 1 | 2012 | 57 | 0.020 |
Why?
| | Peroxidase | 1 | 2012 | 174 | 0.020 |
Why?
| | Cell Membrane | 1 | 2015 | 732 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2012 | 376 | 0.020 |
Why?
| | Dinoprostone | 1 | 2012 | 187 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2018 | 899 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2015 | 1155 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2014 | 713 | 0.020 |
Why?
| | Cerebrovascular Circulation | 1 | 2013 | 227 | 0.020 |
Why?
| | Acute-Phase Proteins | 1 | 2011 | 67 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1028 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 327 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 2685 | 0.020 |
Why?
| | Waiting Lists | 1 | 2012 | 237 | 0.020 |
Why?
| | Hemolysis | 1 | 2011 | 199 | 0.020 |
Why?
| | Indoles | 1 | 2012 | 384 | 0.020 |
Why?
| | Membrane Glycoproteins | 1 | 2011 | 476 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2011 | 742 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2012 | 2117 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2013 | 4886 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2011 | 4076 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2012 | 5439 | 0.010 |
Why?
| | Mice | 1 | 2012 | 16915 | 0.010 |
Why?
|
|
Wohlauer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|